Shuwen Biotech, a Hangzhou-area IVD company, formed a strategic partnership with Germany’s BioNTech Diagnostics that gives Shuwen exclusive rights to commercialize BioNTech’s molecular breast cancer stratification test in China. Shuwen will also be responsible for obtaining CFDA approval of the test. The MammaTyper® test is a molecular diagnostic test, using RNA analysis to measure gene expression, for stratification of breast cancer by molecular subtyping of tumor tissue samples.
